Personalis offers breakthrough personalized cancer testing with its NeXT Personal tumor-informed liquid biopsy, providing highly sensitive MRD detection using minimal cfDNA and tumor tissue. Their assays enable early detection of cancer recurrence, personalized therapy selection, and advanced biomarker strategies for drug development.